Eiger BioPharmaceuticals Future Growth
Future criteria checks 2/6
Eiger BioPharmaceuticals is forecast to grow earnings and revenue by 60.6% and 20.1% per annum respectively while EPS is expected to grow by 67.3% per annum.
Key information
60.6%
Earnings growth rate
67.3%
EPS growth rate
Biotechs earnings growth | 23.5% |
Revenue growth rate | 20.1% |
Future return on equity | n/a |
Analyst coverage | Low |
Last updated | 21 Mar 2024 |
Recent future growth updates
Recent updates
Eiger BioPharmaceuticals, Inc.'s (NASDAQ:EIGR) 28% Dip In Price Shows Sentiment Is Matching Revenues
Apr 01The Market Doesn't Like What It Sees From Eiger BioPharmaceuticals, Inc.'s (NASDAQ:EIGR) Revenues Yet As Shares Tumble 26%
Jan 04Analysts Have Just Cut Their Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Revenue Estimates By 22%
Dec 20Analyst Forecasts For Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Are Surging Higher
Nov 09Rock star Growth Puts Eiger BioPharmaceuticals (NASDAQ:EIGR) In A Position To Use Debt
Oct 06Eiger sheds ~20% on abandonment of EUA request for COVID therapy
Oct 05Eiger falls 21% amid uncertainty over regulatory path for COVID-19 therapy
Sep 06Eiger BioPharmaceuticals: Undervalued Biotech With End Of 2022 Catalyst
Jul 26European Commission approves Eiger BioPharmaceuticals' progeria therapy Zokinvy
Jul 20Eiger Biopharmaceuticals: Value Inflection For Lead Asset In HDV Infection On The Horizon
Apr 06Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Analysts Are More Bearish Than They Used To Be
Mar 15Eiger Pharma: HDV Approval In 2023 Is A Major Catalyst
Dec 26Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 34 | -8 | N/A | N/A | 1 |
12/31/2025 | 33 | -10 | N/A | N/A | 1 |
12/31/2024 | 25 | -25 | N/A | N/A | 1 |
12/31/2023 | 16 | -75 | -75 | -75 | N/A |
9/30/2023 | 15 | -87 | -83 | -83 | N/A |
6/30/2023 | 15 | -96 | -89 | -89 | N/A |
3/31/2023 | 15 | -97 | -89 | -89 | N/A |
12/31/2022 | 13 | -97 | -83 | -83 | N/A |
9/30/2022 | 14 | -93 | -78 | -78 | N/A |
6/30/2022 | 13 | -89 | -76 | -76 | N/A |
3/31/2022 | 11 | -86 | -75 | -75 | N/A |
12/31/2021 | 12 | -34 | -71 | -71 | N/A |
9/30/2021 | 9 | -31 | -70 | -70 | N/A |
6/30/2021 | 6 | -24 | -65 | -65 | N/A |
3/31/2021 | 4 | -21 | -60 | -60 | N/A |
12/31/2020 | N/A | -65 | -63 | -63 | N/A |
9/30/2020 | N/A | -63 | -63 | -63 | N/A |
6/30/2020 | N/A | -66 | -64 | -63 | N/A |
3/31/2020 | N/A | -68 | -63 | -62 | N/A |
12/31/2019 | N/A | -70 | -64 | -64 | N/A |
9/30/2019 | N/A | -70 | -61 | -61 | N/A |
6/30/2019 | N/A | -68 | -60 | -60 | N/A |
3/31/2019 | N/A | -61 | -53 | -53 | N/A |
12/31/2018 | N/A | -52 | -43 | -43 | N/A |
9/30/2018 | N/A | -47 | -41 | -41 | N/A |
6/30/2018 | N/A | -39 | -35 | -35 | N/A |
3/31/2018 | N/A | -40 | -36 | -36 | N/A |
12/31/2017 | N/A | -42 | -38 | -38 | N/A |
9/30/2017 | N/A | -44 | N/A | -39 | N/A |
6/30/2017 | N/A | -47 | N/A | -38 | N/A |
3/31/2017 | N/A | -49 | N/A | -45 | N/A |
12/31/2016 | N/A | -47 | N/A | -38 | N/A |
9/30/2016 | N/A | -41 | N/A | -30 | N/A |
6/30/2016 | N/A | -33 | N/A | -25 | N/A |
3/31/2016 | N/A | -22 | N/A | -12 | N/A |
12/31/2015 | N/A | -13 | N/A | -9 | N/A |
9/30/2015 | N/A | -7 | N/A | -6 | N/A |
12/31/2014 | N/A | -2 | N/A | -1 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: EIGR.Q is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: EIGR.Q is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: EIGR.Q is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: EIGR.Q's revenue (20.1% per year) is forecast to grow faster than the US market (8.2% per year).
High Growth Revenue: EIGR.Q's revenue (20.1% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if EIGR.Q's Return on Equity is forecast to be high in 3 years time